VEGFA and ulcer disease: Peer-reviewed experimental manuscripts are showing that anti-VEGF (primarily bevacizumab given subconjunctivally in alkali-burn models) accelerated restoration of the basement membrane, reduced haze, and improved corneal transparency—i.e., promoted corneal wound/ulcer healing [417,418].